In a first for the dangling accelerated approvals reviewed by FDA’s oncology adcomm in April, Merck on Thursday afternoon agreed to pull a third-line stomach cancer indication for its blockbuster Keytruda after late-stage confirmatory trials failed to show clinical benefit.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,